Otsuka gobbles up more global rights for Akebia’s vadadustat, chipping in to a pot now worth $2B-plus
Late last year Otsuka stepped in with a deal worth more than a billion dollars to partner with Akebia on its experimental anemia drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
